All In Biotech

NDA 212520 · Rvl Pharms

Upneeq

Oxymetazoline Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: May 5, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 8, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

655

76 Phase 3, 27 recruiting

FAERS reports

2,364

105 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2026.

UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. ( 1 )

Mechanism: Oxymetazoline is an alpha adrenoceptor agonist targeting a subset of adrenoreceptors in Mueller’s muscle of the eyelid.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • UPNEEQ · OXYMETAZOLINE HYDROCHLORIDE 0.1% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxymetazoline" as an intervention, any sponsor and status, largest first.

All 655 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective618
  • vision blurred311
  • eye irritation276
  • ocular hyperaemia257
  • off label use199
  • headache197
  • dry eye186
  • eye pain183
  • mydriasis130
  • eye pruritus119
  • lacrimation increased90
  • swelling of eyelid88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202034
2021370
2022439
2023292
2024318
2025274
2026637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 149 on PubMed

Sponsor: Rvl Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.